Research programme: bacterial DNA polymerase III inhibitors - GalapagosAlternative Names: CAM 1; GLPG 1492
Latest Information Update: 27 Jan 2015
At a glance
- Originator Galapagos NV
- Mechanism of Action DNA polymerase III inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections